DE60142562D1 - Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion - Google Patents

Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion

Info

Publication number
DE60142562D1
DE60142562D1 DE60142562T DE60142562T DE60142562D1 DE 60142562 D1 DE60142562 D1 DE 60142562D1 DE 60142562 T DE60142562 T DE 60142562T DE 60142562 T DE60142562 T DE 60142562T DE 60142562 D1 DE60142562 D1 DE 60142562D1
Authority
DE
Germany
Prior art keywords
suppression
polynucleotide sequences
virus infection
hepatitis virus
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142562T
Other languages
German (de)
English (en)
Inventor
Nest Gary Van
Joseph J Eiden Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax Technologies Corp
Original Assignee
Dynavax Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corp filed Critical Dynavax Technologies Corp
Application granted granted Critical
Publication of DE60142562D1 publication Critical patent/DE60142562D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60142562T 2000-03-10 2001-03-12 Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion Expired - Lifetime DE60142562D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18830100P 2000-03-10 2000-03-10
US09/802,370 US20020098199A1 (en) 2000-03-10 2001-03-09 Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
PCT/US2001/007931 WO2001068078A2 (en) 2000-03-10 2001-03-12 Immunostimulatory polynucleotide sequences for use in suppressing hepatitis virus infection

Publications (1)

Publication Number Publication Date
DE60142562D1 true DE60142562D1 (de) 2010-08-26

Family

ID=26883932

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142562T Expired - Lifetime DE60142562D1 (de) 2000-03-10 2001-03-12 Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion

Country Status (9)

Country Link
US (2) US20020098199A1 (enExample)
EP (1) EP1282427B1 (enExample)
JP (1) JP5128745B2 (enExample)
AT (1) ATE473750T1 (enExample)
AU (2) AU2001242032B2 (enExample)
CA (1) CA2402250A1 (enExample)
DE (1) DE60142562D1 (enExample)
ES (1) ES2348877T3 (enExample)
WO (1) WO2001068078A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
AU2002345847B2 (en) 2001-06-21 2008-05-29 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
CA2456328C (en) * 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
NZ538628A (en) * 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CN101948835A (zh) 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN101693890B (zh) 2002-12-23 2012-09-05 戴纳伐克斯技术股份有限公司 免疫刺激序列寡核苷酸和使用方法
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
CN101460620B (zh) 2006-05-31 2012-02-15 东丽株式会社 免疫刺激寡核苷酸及其药物用途
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5616461A (en) 1992-05-14 1997-04-01 Dana-Farber Cancer Institute Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5874089A (en) 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998052962A1 (en) 1997-05-19 1998-11-26 Merck & Co., Inc. Oligonucleotide adjuvant
ATE370740T1 (de) * 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
EP2085090A3 (en) * 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
PT1009413E (pt) 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999056755A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
ATE305507T1 (de) * 1998-05-14 2005-10-15 Coley Pharm Gmbh Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
AU766492B2 (en) 1998-09-18 2003-10-16 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
WO2000062802A2 (en) 1999-04-20 2000-10-26 Smithkline Beecham Biologicals Sa Vaccine comprising rsv antigen and cpg oligonucleotide
AU4978100A (en) 1999-04-29 2000-11-17 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE60041335D1 (de) 1999-08-19 2009-02-26 Dynavax Tech Corp Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
AU781812B2 (en) * 2000-01-13 2005-06-16 Antigenics, Inc. Innate immunity-stimulating compositions of CPG and saponin and methods thereof
WO2001055341A2 (en) 2000-01-31 2001-08-02 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
AU2001241751B2 (en) * 2000-02-23 2005-09-01 Tel Aviv Sourasky Medical Center Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
WO2001072123A1 (en) * 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
CA2405424A1 (en) 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines

Also Published As

Publication number Publication date
US20030216340A1 (en) 2003-11-20
CA2402250A1 (en) 2001-09-20
WO2001068078A3 (en) 2002-09-12
JP5128745B2 (ja) 2013-01-23
JP2003526662A (ja) 2003-09-09
EP1282427B1 (en) 2010-07-14
EP1282427A2 (en) 2003-02-12
ES2348877T3 (es) 2010-12-16
AU2001242032B2 (en) 2005-09-15
WO2001068078A2 (en) 2001-09-20
AU4203201A (en) 2001-09-24
US20020098199A1 (en) 2002-07-25
US7727712B2 (en) 2010-06-01
ATE473750T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
DE60142562D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
DE60142683D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
ATE373084T1 (de) Verfahren zur herstellung von gereinigtem hcv rna durch isolierung von exosomen
TW200502246A (en) Vaccine
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
ATE476984T1 (de) Behandlung von herpes infektion mit anwendung von immunomodulatore polynukleotide sequenzen
ATE326236T1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
IT1278077B1 (it) Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
DE60142775D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ES2187530T3 (es) Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
DOP2003000641A (es) Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
DE69902103D1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DE69106141D1 (de) Non-a non-b sequenzen.
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
MXPA05007901A (es) Terapia de combinacion para hcv.
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
TW369600B (en) Antigenic peptides for grouping hepatitis C virus, kit comprising the same and methods for its grouping the same
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus
Giuggio Characterization of intrahepatic T-lymphocytes in patients with chronic hepatitis C virus infection: a dissertation
ATE388231T1 (de) Fischimpstoff gegen piscirickettsia salmonis